Scaling up and implementing the digital Survivorship Passport tool in routine clinical care - The European multidisciplinary PanCareSurPass project.

Childhood cancer survivors Health Level Seven International Health care provider Implementation Interoperability Long-term follow-up care Person-centred care Routine clinical care Survivorship

Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
May 2024
Historique:
received: 21 12 2023
revised: 11 03 2024
accepted: 14 03 2024
pubmed: 22 3 2024
medline: 22 3 2024
entrez: 21 3 2024
Statut: ppublish

Résumé

Childhood cancer survivors (CCS), of whom there are about 500,000 living in Europe, are at an increased risk of developing health problems [1-6] and require lifelong Survivorship Care. There are information and knowledge gaps among CCS and healthcare providers (HCPs) about requirements for Survivorship Care [7-9] that can be addressed by the Survivorship Passport (SurPass), a digital tool providing CCS and HCPs with a comprehensive summary of past treatment and tailored recommendations for Survivorship Care. The potential of the SurPass to improve person-centred Survivorship Care has been demonstrated previously [10,11]. The EU-funded PanCareSurPass project will develop an updated version (v2.0) of the SurPass allowing for semi-automated data entry and implement it in six European countries (Austria, Belgium, Germany, Italy, Lithuania and Spain), representative of three infrastructure healthcare scenarios typically found in Europe. The implementation study will investigate the impact on person-centred care, as well as costs and processes of scaling up the SurPass. Interoperability between electronic health record systems and SurPass v2.0 will be addressed using the Health Level Seven (HL7) International interoperability standards. PanCareSurPass will deliver an interoperable digital SurPass with comprehensive evidence on person-centred outcomes, technical feasibility and health economics impacts. An Implementation Toolkit will be developed and freely shared to promote and support the future implementation of SurPass across Europe. PanCareSurPass is a novel European collaboration that will improve person-centred Survivorship Care for CCS across Europe through a robust assessment of the implementation of SurPass v2.0 in different healthcare settings.

Sections du résumé

BACKGROUND BACKGROUND
Childhood cancer survivors (CCS), of whom there are about 500,000 living in Europe, are at an increased risk of developing health problems [1-6] and require lifelong Survivorship Care. There are information and knowledge gaps among CCS and healthcare providers (HCPs) about requirements for Survivorship Care [7-9] that can be addressed by the Survivorship Passport (SurPass), a digital tool providing CCS and HCPs with a comprehensive summary of past treatment and tailored recommendations for Survivorship Care. The potential of the SurPass to improve person-centred Survivorship Care has been demonstrated previously [10,11].
METHODS METHODS
The EU-funded PanCareSurPass project will develop an updated version (v2.0) of the SurPass allowing for semi-automated data entry and implement it in six European countries (Austria, Belgium, Germany, Italy, Lithuania and Spain), representative of three infrastructure healthcare scenarios typically found in Europe. The implementation study will investigate the impact on person-centred care, as well as costs and processes of scaling up the SurPass. Interoperability between electronic health record systems and SurPass v2.0 will be addressed using the Health Level Seven (HL7) International interoperability standards.
RESULTS RESULTS
PanCareSurPass will deliver an interoperable digital SurPass with comprehensive evidence on person-centred outcomes, technical feasibility and health economics impacts. An Implementation Toolkit will be developed and freely shared to promote and support the future implementation of SurPass across Europe.
CONCLUSIONS CONCLUSIONS
PanCareSurPass is a novel European collaboration that will improve person-centred Survivorship Care for CCS across Europe through a robust assessment of the implementation of SurPass v2.0 in different healthcare settings.

Identifiants

pubmed: 38513384
pii: S0959-8049(24)00685-3
doi: 10.1016/j.ejca.2024.114029
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114029

Informations de copyright

Copyright © 2024. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Anna-Liesa Filbert (AL)

Division of Childhood Cancer Epidemiology, German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.

Leontien Kremer (L)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Ruth Ladenstein (R)

St. Anna Children's Cancer Research Institute, Vienna, Austria; St Anna Children's Hospital, Vienna, Austria.

Catherine Chronaki (C)

HL7 Europe, Brussels, Belgium.

Alexander Degelsegger-Márquez (A)

Gesundheit Österreich GmbH, Vienna, Austria.

Heleen van der Pal (H)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Edit Bardi (E)

St Anna Children's Hospital, Vienna, Austria; Department of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz, Kepler University Hospital, Linz, Austria.

Anne Uyttebroeck (A)

University Hospitals Leuven, KU Leuven, Belgium.

Thorsten Langer (T)

Universitatsklinikum Schleswig-Holstein, Campus Lubeck, Germany.

Monica Muraca (M)

IRCCS Istituto Giannina Gaslini, Genova, Italy.

Adela Cañete Nieto (AC)

Hospital Universitario y Politécnico La Fe, Valencia, Spain.

Jelena Rascon (J)

Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania; Clinics for Children's Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Lithuania.

Francesca Bagnasco (F)

IRCCS Istituto Giannina Gaslini, Genova, Italy.

Stefan Beyer (S)

AIT Austrian Institute of Technology, Graz, Austria.

Jeroen Te Dorsthorst (J)

PanCare, Bussum, the Netherlands.

Samira Essiaf (S)

SIOP Europe, Brussels, Belgium.

Antonio Orduña Galan (AO)

Instituto Investigación Sanitaria La Fe, Valencia, Spain.

Anita Kienesberger (A)

CCI Europe, Vienna, Austria.

Kylie O'Brien (K)

Pintail, Dublin, Ireland.

Marisa Correcher Palau (MC)

Instituto Investigación Sanitaria La Fe, Valencia, Spain.

Saskia M F Pluijm (SMF)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Sonia di Profio (S)

Clinical Psychology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.

Davide Saraceno (D)

CINECA Interuniversity Consortium, Italy.

Carina Schneider (C)

CCI Europe, Vienna, Austria.

Günter Schreier (G)

AIT Austrian Institute of Technology, Graz, Austria.

Justas Trinkūnas (J)

Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.

Igor Zamberlan (I)

Liguria Digitale S.p.A., Italy.

Desiree Grabow (D)

Division of Childhood Cancer Epidemiology, German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany. Electronic address: desiree.grabow@uni-mainz.de.

Riccardo Haupt (R)

IRCCS Istituto Giannina Gaslini, Genova, Italy.

Classifications MeSH